S-Methyl-L-(+)-Cystein-methylester | 3830-10-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: S-Methyl-L-(+)-Cystein-methylester
• 英文别名: S-methyl-L-cysteine methyl ester；methyl S-methyl-L-cysteinate；methyl (2R)-2-amino-3-methylthiopropanoate；methyl (2R)-2-amino-3-methylsulfanylpropanoate
• CAS: 3830-10-2
• 化学式: C₅H₁₁NO₂S
• 分子量: 149.214
• InChiKey: OMBVLJSHPJLTKD-BYPYZUCNSA-N

物化性质

• 沸点：
  223.1±30.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  77.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  S-Methyl-L-(+)-Cystein-methylester 在 钯 氢气 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Asp-Cys(S-CH3)-O-CH3
  参考文献：
  名称：

  一些二肽的结构-味道关系。

  摘要：

  DOI：

  10.1021/ja01038a046
• 作为产物：
  描述：

  L-半胱氨酸 、 碘甲烷 在 sodium hydroxide 作用下， 生成 S-Methyl-L-(+)-Cystein-methylester
  参考文献：
  名称：

  尝试合成头孢菌素衍生物，制备反式-3-磺酰氧基-4-烷硫基-2-氮杂环丁烷酮

  摘要：

  在三乙胺的存在下，磺酰氧基乙酰氯1与硫代酰亚胺酯2反应形成反式-3-磺酰氧基-4-烷基硫基-2-氮杂环丁酮3。这类新的β-内酰胺衍生物的另一种途径是酰氧基乙酰氯8与硫代亚磺酸酯2的反应，3-酰氧基-2-氮杂环丁烷酮9的皂化反应，生成3-羟基化合物10以及它们与磺酸的酯化反应。酰氯。所示的β-内酰胺中硫和氮的不饱和残基被臭氧氧化形成羰基官能团。的Δ反应2 -thiazolines和5,6-二氢-4-氧代描述了H -1，3-噻嗪与磺酰氧基乙酰氯形成双环β-内酰胺衍生物。

  DOI：

  10.1002/jlac.197419740605
• 作为试剂：
  描述：

  在 S-Methyl-L-(+)-Cystein-methylester 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以84%的产率得到
  参考文献：
  名称：

  Total Synthesis of Maremycins A and D1 Using Chiral and Cyclic Nitrone with (E)-3-Ethylidene-1-methylindolin-2-one

  摘要：

  Total syntheses of maremycin A (4) and maremycin D, (8) were described, featuring 1,3-dipolar cycloaddition of a chiral cyclic nitrone 15 with (E)-3-ethylidene-1-methylindolin-2-one (13). The cycloaddition was reversible, especially at high temperature in the presence of a Lewis acid or in a solvent possessing a high acceptor number. One of the cycloadducts was efficiently led to maremycin A (4) and maremycin D, (8). High optical purity of 4 was confirmed by chiral HPLC comparison with ent-4 prepared from ent-15 and 13.

  DOI：

  10.3987/com-14-s(k)93

文献信息

• Dioxacycloalkane compound having renin-inhibitory activity
  申请人：Japan Tobacco Inc.

  公开号：US05750696A1

  公开（公告）日：1998-05-12

  Dioxacycloalkane compounds of the formula \x9b1! ##STR1## wherein A is ##STR2## wherein W is ##STR3## X is --CO-- or --SO.sub.2 --; Y is --CH.sub.2 --, --O-- or --NR.sup.25 --; and R.sup.1 is an aralkyl which may be substituted by lower alkoxy; R.sup.2 is a hydrogen atom or a lower alkyl; R.sup.3 is --(CH.sub.2)d-SR.sup.26 or ##STR4## R.sup.4 and R.sup.5 are each a hydrogen atom or a lower alkyl; and E is --C(R.sup.29)(R.sup.30)-- or --CH.sub.2 CH.sub.2 --, pharmaceutically acceptable salts thereof, intermediates for producing said compounds, and methods for producing said intermediates. The compounds of the formula \x9b1! have a strong inhibitory activity against renin and show continuous hypotensive action by oral administration. They are useful as hypotensive agents or therapeutic agents for heart failure.

  二氧杂环戊烷化合物的化学式为\x9b1! ##STR1## 其中A为##STR2## 其中W为##STR3## X为--CO--或--SO.sub.2--; Y为--CH.sub.2--, --O--或--NR.sup.25--; R.sup.1为可以被较低烷氧基取代的芳基烷基; R.sup.2为氢原子或较低烷基; R.sup.3为--(CH.sub.2)d-SR.sup.26或##STR4## R.sup.4和R.sup.5分别为氢原子或较低烷基; E为--C(R.sup.29)(R.sup.30)--或--CH.sub.2 CH.sub.2--, 其药用盐，用于制备所述化合物的中间体，以及制备所述中间体的方法。该化合物的化学式\x9b1! 具有强抑制肾素的活性，并通过口服显示持续的降压作用。它们可用作降压剂或治疗心力衰竭的药物。
• [EN] COMPOUNDS AND METHODS USE<br/>[FR] COMPOSÉS ET MÉTHODES D'UTILISATION
  申请人：SIGNUM BIOSCIENCES INC

  公开号：WO2018132759A1

  公开（公告）日：2018-07-19

  The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.

  本发明提供了用于治疗或预防炎症、痤疮、细菌感染并促进健康皮肤外观的化合物，以及包含这些化合物的组合物。
• SAC 유도체 또는 SMC 유도체를 포함하는 피부 각질형성세포 분화 촉진용 조성물
  申请人：CHAMEDITECH Co., Ltd. 주식회사 차메디텍(120130625620) Corp. No ▼ 160111-0353401BRN ▼314-86-50515

  公开号：KR20200143824A

  公开（公告）日：2020-12-28

  본 발명은 피부 각질형성세포 분화 촉진용 조성물에 관한 것으로, 더욱 상세하게는 SAC 유도체 또는 SMC 유도체를 유효성분으로 포함함으로써 피부 각질형성세포 분화를 촉진하여 주름개선 효능이 우수하며, 주근깨 및 기미 완화, 피부재생, 피부장벽 회복 효과가 있으며, 약학, 화장료, 비누, 바디용, 샴푸 및 팩에 이용 가능한 조성물에 관한 것이다.

  This is a patent related to a composition for promoting the differentiation of skin corneocytes, more specifically, by including SAC derivatives or SMC derivatives as active ingredients to promote the differentiation of skin corneocytes, it has excellent wrinkle improvement efficacy, as well as freckle and blemish alleviation, skin regeneration, and skin barrier restoration effects. It relates to a composition that can be used in pharmaceuticals, cosmetics, soaps, body care products, shampoos, and masks.
• Cysteine derivatives
  申请人：Mitsubishi Chemical Industries, Limited

  公开号：US04440788A1

  公开（公告）日：1984-04-03

  This invention relates to S-alkylcysteines and processes for preparing same. The compounds according to this invention are expected to be applicable as therapeutic agents for hepatic failures.

  这项发明涉及S-烷基半胱氨酸及其制备方法。根据这项发明的化合物预计可用作治疗肝功能衰竭的药物。
• Design, Synthesis and X-ray Structure of Protein−Ligand Complexes:  Important Insight into Selectivity of Memapsin 2 (β-Secretase) Inhibitors
  作者：Arun K. Ghosh、Nagaswamy Kumaragurubaran、Lin Hong、Hui Lei、Khaja Azhar Hussain、Chun-Feng Liu、Thippeswamy Devasamudram、Vajira Weerasena、Robert Turner、Gerald Koelsch、Geoffrey Bilcer、Jordan Tang

  DOI：10.1021/ja058636j

  日期：2006.4.1

  Structure-based design, synthesis, and X-ray structure of protein−ligand complexes of memapsin 2 are described. The inhibitors are designed specifically to interact with S2- and S3-active site residues to provide selectivity over memapsin 1 and cathepsin D. Inhibitor 6 has exhibited exceedingly potent inhibitory activity against memapsin 2 and selectivity over memapsin 1 (>3800-fold) and cathepsin

  描述了 memapsin 2 蛋白质-配体复合物的基于结构的设计、合成和 X 射线结构。这些抑制剂专门设计用于与 S2 和 S3 活性位点残基相互作用，以提供对 memapsin 1 和组织蛋白酶 D 的选择性。抑制剂 6 对 memapsin 2 表现出极强的抑制活性，并且对 memapsin 1（>3800 倍）和组织蛋白酶具有选择性D（>2500 倍）。蛋白质-配体晶体结构揭示了 memapsin 2 的 S2 和 S3 活性位点中的协同相互作用。这些相互作用可以作为设计 memapsin 1 和组织蛋白酶 D 选择性的重要指南。